Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

NCT06940661 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Granulomatosis With Polyangiitis

Interventions

DRUG: Obinutuzumab

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]